MAPT and Alzheimer disease: According to the recommendation by the National Institute of Neurological and Communicative Disorders and Stroke–AD and Related Disorders Association (NINCDS-ADRDA) Work Group, the clinical classification of AD should explore the image markers: magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), positron emission tomography (PET), amyloid-PET, tau-PET, and abnormal neuronal cerebrospinal fluid (CSF) markers (tau and/or Aβ) (Dubois et al., 2007; Leandrou et al., 2018; Liu et al., 2018a,b).